News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
831,523 Results
Type
Article (76625)
Company Profile (649)
Press Release (754235)
Multimedia
Podcasts (150)
Webinars (20)
Section
Business (229219)
Career Advice (3786)
Deals (39417)
Drug Delivery (131)
Drug Development (89831)
Employer Resources (200)
FDA (18022)
Job Trends (17212)
News (390461)
Policy (39048)
Tag
Academia (3001)
Academic (2)
Accelerated approval (15)
Adcomms (33)
Allergies (111)
Alliances (56450)
ALS (123)
Alzheimer's disease (1619)
Antibody-drug conjugate (ADC) (192)
Approvals (17990)
Artificial intelligence (389)
Autoimmune disease (38)
Automation (22)
Bankruptcy (404)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (139)
Biotechnology (443)
Bladder cancer (109)
Brain cancer (44)
Breast cancer (414)
Cancer (3278)
Cardiovascular disease (263)
Career advice (3229)
Career pathing (34)
CAR-T (218)
CDC (43)
Cell therapy (595)
Cervical cancer (26)
Clinical research (73602)
Collaboration (1182)
Company closure (4)
Compensation (789)
Complete response letters (42)
COVID-19 (2918)
CRISPR (71)
C-suite (417)
Cystic fibrosis (126)
Data (3354)
Decentralized trials (2)
Denatured (53)
Depression (83)
Diabetes (388)
Diagnostics (7006)
Digital health (24)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (173)
Drug pricing (161)
Drug shortages (36)
Duchenne muscular dystrophy (171)
Earnings (96434)
Editorial (50)
Employer branding (25)
Employer resources (169)
Events (130926)
Executive appointments (933)
FDA (20065)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (11)
Funding (1050)
Gene editing (154)
Generative AI (36)
Gene therapy (473)
GLP-1 (962)
Government (5274)
Grass and pollen (7)
Guidances (322)
Healthcare (20906)
HIV (46)
Huntington's disease (32)
IgA nephropathy (48)
Immunology and inflammation (197)
Immuno-oncology (15)
Indications (43)
Infectious disease (3124)
Inflammatory bowel disease (169)
Inflation Reduction Act (13)
Influenza (79)
Intellectual property (140)
Interviews (742)
IPO (17842)
IRA (58)
Job creations (5031)
Job search strategy (2632)
Kidney cancer (14)
Labor market (63)
Layoffs (607)
Leadership (27)
Legal (9979)
Liver cancer (87)
Longevity (12)
Lung cancer (455)
Lymphoma (234)
Machine learning (15)
Management (65)
Manufacturing (492)
MASH (106)
Medical device (14755)
Medtech (14766)
Mergers & acquisitions (22352)
Metabolic disorders (997)
Multiple sclerosis (107)
NASH (23)
Neurodegenerative disease (165)
Neuropsychiatric disorders (48)
Neuroscience (2430)
NextGen: Class of 2025 (7644)
Non-profit (5092)
Now hiring (52)
Obesity (507)
Opinion (298)
Ovarian cancer (108)
Pain (136)
Pancreatic cancer (136)
Parkinson's disease (206)
Partnered (24)
Patents (352)
Patient recruitment (206)
Peanut (55)
People (64991)
Pharmaceutical (134)
Pharmacy benefit managers (25)
Phase I (22725)
Phase II (32074)
Phase III (24189)
Pipeline (2176)
Policy (261)
Postmarket research (3299)
Preclinical (10105)
Press Release (72)
Prostate cancer (159)
Psychedelics (46)
Radiopharmaceuticals (278)
Rare diseases (554)
Real estate (7210)
Recruiting (76)
Regulatory (26788)
Reports (63)
Research institute (2663)
Resumes & cover letters (590)
Rett syndrome (10)
RNA editing (13)
RSV (62)
Schizophrenia (111)
Series A (176)
Series B (127)
Service/supplier (27)
Sickle cell disease (69)
Special edition (22)
Spinal muscular atrophy (167)
Sponsored (38)
Startups (4228)
State (2)
Stomach cancer (17)
Supply chain (86)
Tariffs (75)
The Weekly (95)
Vaccines (952)
Venture capital (62)
Weight loss (346)
Women's health (52)
Worklife (20)
Date
Today (176)
Last 7 days (751)
Last 30 days (2601)
Last 365 days (33354)
2025 (20654)
2024 (37926)
2023 (42567)
2022 (53928)
2021 (58723)
2020 (57665)
2019 (51316)
2018 (39099)
2017 (36903)
2016 (37862)
2015 (43886)
2014 (38728)
2013 (34870)
2012 (36730)
2011 (36815)
2010 (36488)
Location
Africa (1211)
Alabama (73)
Alaska (7)
Arizona (269)
Arkansas (14)
Asia (49413)
Australia (8488)
California (8342)
Canada (2540)
China (762)
Colorado (357)
Connecticut (370)
Delaware (222)
Europe (112049)
Florida (1247)
Georgia (284)
Hawaii (3)
Idaho (66)
Illinois (752)
India (34)
Indiana (407)
Iowa (19)
Japan (250)
Kansas (117)
Kentucky (34)
Louisiana (20)
Maine (74)
Maryland (1164)
Massachusetts (6342)
Michigan (281)
Minnesota (514)
Mississippi (4)
Missouri (109)
Montana (32)
Nebraska (26)
Nevada (91)
New Hampshire (75)
New Jersey (2311)
New Mexico (31)
New York (2299)
North Carolina (1289)
North Dakota (10)
Northern California (3658)
Ohio (266)
Oklahoma (17)
Oregon (46)
Pennsylvania (1778)
Puerto Rico (18)
Rhode Island (42)
South America (1579)
South Carolina (39)
South Dakota (1)
Southern California (3134)
Tennessee (135)
Texas (1271)
United States (31167)
Utah (244)
Virginia (224)
Washington D.C. (80)
Washington State (717)
West Virginia (4)
Wisconsin (87)
831,523 Results for "jiangsu atom bioscience and pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Press Releases
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.
August 12, 2025
·
6 min read
Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3
October 9, 2023
·
3 min read
Business
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China
Mycovia Pharmaceuticals, Inc. today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC).
February 7, 2024
·
7 min read
Press Releases
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions
June 17, 2025
·
4 min read
Atom Bioscience Marks Gout Awareness Day with Video Detailing Risks of Hyperuricemia, the Cause of Gout
Atom Bioscience, a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of the dangers of chronic gout to help mark Gout Awareness Day, May 22, 2024.
May 21, 2024
·
2 min read
Press Releases
Univar Solutions and Shandong Head Group Co., Ltd. Establish Exclusive European Partnership to Enhance Supply of Cellulose Ethers and Pharmaceutical Excipients
May 22, 2025
·
7 min read
Bio NC
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China
Mycovia Pharmaceuticals, Inc. today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) received approval in June from the National Medical Products Administration for Oteseconazole Capsules, an azole antifungal, indicated for the treatment of severe vulvovaginal candidiasis (VVC).
August 21, 2023
·
7 min read
Business
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
Teva Pharmaceutical Investments Singapore Pte Ltd, a subsidiary of Teva Pharmaceutical Industries Ltd. and Jiangsu Nhwa Pharmaceutical Co., Ltd announced it formed a partnership for the marketing and distribution of Teva’s AUSTEDO for the treatment of neurodegenerative and movement disorders - chorea associated with Huntington’s disease and tardive dyskinesia in adults.
February 26, 2024
·
6 min read
Press Releases
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
August 7, 2025
·
4 min read
1 of 83,153
Next
